NXTC insider trading
HealthcareNextCure, Inc.: insider trade history from SEC Form 4 filings.
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Company website: www.nextcure.com
NXTC insider activity at a glance
FilingIQ tracks 46 insider transactions for NXTC in filings since May 13, 2019. The most recent transaction is dated Aug 10, 2026.
Across the full history, 20 open-market purchases
and 1 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest NXTC Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Most active insiders at NXTC
By number of Form 4 lines in the last 180 days.
Frequently asked
- How many insider trades does FilingIQ track for NXTC?
- FilingIQ tracks 46 Form 4 insider transactions for NXTC (NextCure, Inc.), covering filings from May 13, 2019 onwards. 14 of those are dated within the last 90 days.
- Are NXTC insiders net buyers or net sellers?
- Across the full Form 4 history for NXTC, 20 transactions (43%) were open-market purchases and 1 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does NXTC insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is NXTC in?
- NextCure, Inc. (NXTC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $45.99M.
Methodology & sources
Every NXTC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.